Adam Feuerstein on Muck Rack

Adam Feuerstein Verified

As seen in:  The Street

Sr. Columnist at TheStreet, aka the Col. Jessup of biotech/drug stocks. Data Are. I curse. Said one analyst: The likes of Adam Feuerstein attack viciously.

Biotech Stock Mailbag: ASCO Preview, CAR-T stocks, MannKind, Hate Mail!

thestreet.com — BOSTON ( TheStreet) -- Troy D. writes, " Are you attending the ASCO cancer meeting? What do you think will be the biggest moving stocks to come out of it?" Absolutely. I'm flying to Chicago in a week to attend the American Society of Clinical Oncology annual meeting.

IsoRay (ISR) Takes Liberties With Lung Cancer Study Results to Prop Up Stock Price

thestreet.com — RICHLAND, Wash. ( TheStreet) -- does a poor job selling radioactive "seeds" for use in cancer radiation therapy. To make up for the inability to deliver revenue growth -- and prop up its stock price -- IsoRay issues a lot of promotional press releases, some of which take liberties with clinical data using clever, selective editing.

Bluebird Bio First Look at Gene Therapy for Sickle Cell Disease

thestreet.com — CAMBRIDGE, Mass. ( TheStreet) -- Bluebird Bio's gene therapy administered once to a patient with sickle cell anemia is increasing the number of normally functioning red blood cells and is just barely at the level believed necessary to have a curative effect on the inherited blood disease.

FDA Tells Sarepta Therapeutics: Come on Down With Your DMD Drug!

thestreet.com — CAMBRIDGE, Mass. ( TheStreet) -- Sarepta Therapeutics received the green light from U.S. regulators to finally file a new drug application for eteplirsen, the company's experimental therapy for Duchenne muscular dystrophy (DMD), Sarepta said Tuesday. Portions of the eteplirsen approval application will be submitted to the U.S.

An Open Letter to Sell-Sider Backtracking on Kite Pharma Questions

thestreet.com — Dear Tom Shrader: Did the management team at Kite Pharma yell at you? Did your boss at Stifel Nicolaus yell at you? I ask because I'm interested in hearing the explanation for your "I'm sorry" research note on Kite published Tuesday. I much preferred the research note on Kite you wrote on Monday.

Bluebird Bio (BLUE), Intercept Pharma (ICPT) Reach Accords on Pivotal Trial Designs

thestreet.com — BOSTON ( TheStreet) -- Bluebird Bio and Intercept Pharmaceuticals have reached separate agreements with regulators on the design of pivotal clinical trials intended to get their respective gene therapy and fatty liver disease drugs approved. For BlueBird, the path to European approval for its gene therapy in beta-thalassemia, a rare blood disorder, could be relatively short and may not involve new clinical trials.

Gilead Sciences Buying Achillion Was Twitter Speculation at its Finest

thestreet.com — BOSTON (TheStreet) -- For a brief moment, and mostly on Twitter, Gilead Sciences was buying Achillion Pharmaceuticals . The speculation of another hepatitis C-related acquisition took off Monday afternoon, sparked by a rumor that Gilead executives canceled a scheduled Tuesday presentation at a healthcare investor conference.

Celgene's (CELG) Crohn's Disease Drug Prompts Lingering Questions

thestreet.com — SUMMIT, NJ ( TheStreet) -- Mongersen is one of Celgene's most important pipeline drugs and a potential blockbuster treatment for Crohn's disease, an autoimmune disorder affecting the bowel. Investors, however, will wait longer than expected for data necessary to resolve a lingering concern about mongersen's potential.

Investors Get Teary over Eleven Bio Dry-Eye Drug Failure

thestreet.com — Eleven Biotherapeutics' stock price began Monday at $11 but it will not end there following the late-stage study failure of an experimental drug to treat dry eye disease. The Eleven Bio drug EBI-005 was unable to prevent damage to the cornea or reduce eye pain compared to a control, the company said Monday.

10 Important Checkpoint Inhibitor Cancer Drug Abstracts from ASCO '15

thestreet.com — CHICAGO ( The Street) -- For the past few years, the American Society of Clinical Oncology (ASCO) annual meeting has been dominated by cancer immunotherapy -- drugs which activate the body's own immune system to identify and kill cancer cells.
More Articles →
May 25, 2015

The day when Texas Gov. Gregg Abbott asks Obama for help dealing with the floods…. pic.twitter.com/h3enY6gQ6X

May 25, 2015

RT @llcandyman: There are few things that piss me off more than the fact that @adamfeuerstein has a lucrative career. Literally thrives off of bullshit

May 25, 2015

. @BioDueDiligence @DewDiligence FDA Adcomm to reinstate Tysabri was spread over 2 days, in part to accommodate MS patient testimony. $BIIB

May 23, 2015

My daughter is 17 today. She’s so grown up. Her birthday doesn’t make me feel old. It makes me feel incredibly proud and lucky. Love.

May 22, 2015

Mike Huckabee can always go back to making infomercials for fake diabetes cures.

May 22, 2015

RT @ggreeneva: … and Mike Huckabee on a child molester. Nothing to add, really. pic.twitter.com/Lud5Cf07kW

Email Adam by joining Muck Rack Pro



Are You a Journalist?

Make a Portfolio

Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.


Share This Profile